KalVista Pharmaceuticals
KALV
KALV
94 hedge funds and large institutions have $310M invested in KalVista Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
94
Holders Change
+6
Holders Change %
+6.82%
% of All Funds
1.48%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
18
Increased
34
Reduced
23
Closed
12
Calls
$740K
Puts
$959K
Net Calls
-$219K
Net Calls Change
-$225K
Top Buyers
1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.85M |
2 |
Citadel Advisors
Miami,
Florida
|
+$6.46M |
3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$2.61M |
4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.66M |
5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
+$1.22M |
Top Sellers
1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.6M |
2 |
PM
Prosight Management
Dallas,
Texas
|
-$1.89M |
3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.83M |
4 |
JFG
Jefferies Financial Group
New York
|
-$1.53M |
5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.39M |